Coherus Oncology (CHRS) EBT Margin Growth (1y) (2014 - 2026)
Powered by 
Analysis
Coherus Oncology (CHRS) EBT Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -801,907.00 |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | 20,443.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20,443.00 |
| Mar 31, 2026 | 32,370.00 |
| Dec 31, 2025 | 23,249.00 |
| Sep 30, 2025 | 40,177.00 |
| Jun 30, 2025 | 9,523.00 |
| Mar 31, 2025 | 232,409.00 |
| Dec 31, 2024 | -50,903.00 |
| Sep 30, 2024 | -73,283.00 |
| Jun 30, 2024 | -45,973.00 |
| Mar 31, 2024 | -271,436.00 |
| Dec 31, 2023 | 4,278.00 |
| Sep 30, 2023 | 13,709.00 |
| Jun 30, 2023 | 1,036.00 |
| Mar 31, 2023 | -7,364.00 |
| Dec 31, 2022 | -6,747.00 |
| Sep 30, 2022 | -14,406.00 |
| Jun 30, 2022 | -4,926.00 |
| Mar 31, 2022 | 4,845.00 |
| Dec 31, 2021 | -7,208.00 |
| Sep 30, 2021 | -7,146.00 |